Pathophysiological basis of albumin use in cirrhosis

Annals of Hepatology

Volumn 10, Issue SUPPL. 1, 2011, Pages

  Arroyo, Vicente ^a   Fernandez, Javier ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

BacterialInfection; LiverFailure; Microcirculation; Paracentesis; Splanchnic

Indexed keywords

ALBUMIN; FUROSEMIDE; SPIRONOLACTONE;

ARTICLE; BACTERIAL INFECTION; BRAIN EDEMA; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; EDEMA; HEART OUTPUT; HEART PRELOAD; HUMAN; HYPOVOLEMIA; KIDNEY FAILURE; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER ISCHEMIA; MICROCIRCULATION; NEPHROTIC SYNDROME; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOSING GASTROENTEROPATHY;

EID: 79956006709     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31600-x     Document Type: Article

References (54)

1. European Association for the Study of the Liver, Ginès P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, Merkel C, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
2. Rothschild MA, Oratz M, Schreiber SS. Albumin metabolism. Prog Liver Dis 1972; 4: 19-29.
3. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005; 57: 787-96.
4. Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH. Ligand binding strategies of human serum albumin: how can the cargo be utilized? Chirality 2010; 22: 77-87.
5. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatol 2005; 41: 1211-9.
6. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallstrom S, Lackner C, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Act 2008; 1782: 469-73.
7. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008; 582: 1783-7.
8. Shawcross DL, Wright GA, Stadlbauer V, Hodges SJ, Davies NA, Wheeler-Jones C, Pitsillides AA, et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatol 2008; 48: 1202-12.
9. Cicco G, Cicco S. The influence of oxygen supply, hemor-heology and microcirculation in the heart and vascular systems. Adv Exp Med Biol 2010; 662: 33-9.
10. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrosis. Hepatol 1998; 8: 1151-7.
11. Arroyo V, Fernández J, Ginés P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28-81-95.
12. Ruiz del Arbol L, Monescillo A, Jimenez W, Garcia Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterol 1997; 113: 579-86.
13. Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, Torres M, et al. Randomized comparative study of therapeutic paracentesis with and without albumin in cirrhosis. Gastroenterol 1988; 94: 1494-502.
14. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Do-mènech E, Abecasis R, Angeli P, et al. Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroen-terol 1996; 114: 1002-10.
15. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
16. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome. Gut 2007; 56: 1310-8.
17. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome; results of a prospective non-randomized study. Hepatol 2002; 36: 941-8.
18. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatol 2010; 51: 576-84.
19. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
20. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatol 1994; 20: 1343-50.
21. Bruix J, Bosch J, Kravetz D, Mastai R, Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemody-namics in patients with cirrhosis of the liver. Gastroente-rol 1985; 88: 430-5.
22. Fernández-Rodriguez CM, Prieto J, Quiroga J, Zozoya JM, Andrade A, Núñez M, Sangro B, et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepa-tol 1995; 21: 35-40.
23. De las Heras D, Fernández J, Ginès P, Cárdenas A, Ortega R, Navasa M, Barberá JA, et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatol 2003; 38: 452-9.
24. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12: 118-23.
25. Caraceni P, Domenicali M, Giannone F, Bernardi M. The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab 2009; 23: 65-77.
26. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-20.
27. Paternostro C, David E, Novo E, Parola M. Hypoxia, angio-genesis and liver fibrogenesis in the progression of chronic liver disease. WJ Gastroenterol 2010; 16: 281-8.
28. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatol 2009; 49: 1245-5.
29. Ruiz-del-Arbol L, Urman J, Fernández J, González M, Nava-sa M, Monescillo A, Albillos A, et al. Systemic, renal and hepatic hemodynamics derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8.
30. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatol 2005; 42: 439-47.
31. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepa-tol 2010; 53: 179-90.
32. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28: 59-69.
33. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francito-rra A, Rimola A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatol 1994; 20: 1495-501.
34. Saitoh T, Ogawa Y, Aoki K, Shibata S, Otsubo A, Kato J, Iwasaki K. Bell-shaped relationship between central blood volume and spontaneous baroreflex function. Auton Neu-rosci 2008; 143: 46-52.
35. Wiest R, Garcia-Tsao G. Bacterial translocation in cirrhosis. Hepatol 2005; 41: 422-33.
36. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med 2008; 29: 119-29.
37. Cichoz-Lach H, Celinski K, Slomka M, Kasztelan-Szczer-binska B. Pathophysiology of portal hypertension. J Phy-siol Pharmacol 2008; 59(Suppl. 2): 231-8.
38. Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, Ríos J, Torres F, Rami L, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analisis. Am J Gas-troenterol 2009; 104: 1382-9.
39. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatol 1996; 23: 164-76.
40. Guevara M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, Jiménez W, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatol 1998; 28: 39-44.
41. Ahl B, Weissenborn K, van den Hoff J, Fischer-Wasels D, Köstler H, Hecker H, Burchert W. Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatol 2004; 40: 73-9.
42. Iversen P, Sørensen M, Bak LK, Waagepetersen HS, Va-faee MS, Borghammer P, Mouridsen K, et al. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterol 2009; 136: 863-71.
43. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatol 2006; 43: 673-81.
44. Marik PE, Gayowski T, Starzl TE. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005; 33: 1254-59.
45. Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatol 2006; 44: 1288-95.
46. Luca A, García-Pagán JC, Bosch J, Feu F, Jiménez W, Ginés A, Fernández M, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatol 1995; 22: 753-8.
47. Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterol 2005; 129: 1944-5.
48. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Maz-za E, Salines F, et al. A. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical feature. Hepatol 2007; 45: 223-9.
49. Ramírez MJ, Ibáñez A, Navasa M, Casals E, Morales-Ruiz M, Jiménez W, Arroyo V, et al. High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. J Hepatol 2004; 40: 424-30.
50. Navasa M, Follo A, Filella X, Jiménez W, Francitorra A, Pla-nas R, Rimola A, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatol 1998; 27: 1227-32.
51. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, Muravsky V, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatol 2009; 50: 555-64.
52. Arroyo V. Human serum albumin: not just a plasma volume expander. Hepatol 2009; 50: 355-7.
53. Fernández J, Navasa M, Garcia-Pagan JC, G-Abraldes J, Ji-ménez W, Bosch J, Arroyo V. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004; 41: 384-90.
54. Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, Navasa M. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatol 2005; 42: 627-34.